Dynavax Technologies | DVAX - Sales Revenues


Dynavax Technologies reported $94.9M in Sales Revenues for its fiscal quarter ending in September of 2025.



Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Adma Biologics USD 139.16M 4.94M Dec/2025
Agenus USD 34.2M 3.97M Dec/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Glaxosmithkline GBP 11.46B 59.16M Dec/2025
Merck USD 16.4B 880M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 24.12M 635K Sep/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
TG Therapeutics USD 192.57M 30.87M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025